Shopping Cart 0
Cart Subtotal
USD 0

CSL Ltd (CSL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of bleeding disorders such as hemophilia and von Willebrand disease, hereditary angioedema, primary and secondary immune deficiencies, inherited respiratory disease and neurological disorders; influenza vaccine; and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns and infection in solid organ transplant recipients and to treat specific infections and help victims of trauma, shock and burns. CSL also markets an array of vaccines, anti-venoms, and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the UK, the US and rest of the world. CSL is headquartered in Parkville, Victoria, Australia.

CSL Ltd (CSL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

CSL Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13

CSL Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

CSL Ltd, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 19

Venture Financing 23

Calimmune Raises USD15 Million in Series B Financing 23

Partnerships 24

CSL Enters into Agreement with Vitaeris 24

PaxVax Enters into Distribution Agreement with Seqirus 25

Seqirus Enters into Distribution Agreement with Valneva 26

A1M Pharma Enters into Research Agreement with CSL Behring 27

PaxVax Enters into Distribution Agreement with BioCSL 28

Alk Abello Enters into Co-Marketing Agreement with BioCSL 29

ALK-Abello Enters into Agreement with Seqirus 30

Licensing Agreements 31

Seqirus Enters into Licensing Agreement with Glenmark Specialty 31

CSL Enters into Licensing Agreement with Cevec Pharma 32

CSL Enters into Licensing Agreement with Momenta Pharma 33

Seqirus Enters into Licensing Agreement with Zambon 35

Calimmune Enters into Licensing Agreement with Cincinnati Children's Hospital Medical Center 36

Calimmune Enters into Licensing Agreement with Asklepios BioPharma 37

Calimmune Enters into Licensing Agreement with St. Jude Children's Research Hospital 38

BioCryst Pharma Enters into Licensing Agreement with Seqirus 39

Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 41

CSL Enters Into Licensing Agreement With Janssen For CSL-362 42

CSL Enters into Licensing Agreement with Xencor 43

Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 44

Debt Offering 45

CSL Raises USD200 Million in Private Placement of 3.32% Debt Securities Due 2029 45

CSL Raises USD150 Million in Private Placement of 3.47% Debt Securities Due 2032 46

CSL Raises USD100 Million in Private Placement of 3.77% Debt Securities Due 2037 47

CSL Raises USD250 Million in Private Placement of 3.17% Debt Securities Due 2027 48

CSL Raises USD258 Million in Private Placement of 0.955% Debt Securities Due 2025 49

CSL Raises USD155 Million in Private Placement of 0.755% Debt Securities Due 2023 50

CSL Raises USD100 Million in Private Placement of 3.63% Debt Securities Due 2025 51

CSL Raises USD200.5 Million in Private Placement of 1.93% Debt Securities Due 2024 52

CSL Raises USD134 Million in Private Placement of 2.1% Debt Securities Due 2026 53

CSL Raises USD134 Million in Private Placement of 1.65% Debt Securities Due 2022 54

CSL Completes Private Placement Of Debt Securities Due 2023 For USD 150 Million 55

CSL Completes Private Placement Of Debt Securities Due 2018 For USD 100 Million 56

CSL Completes Private Placement Of Debt Securities Due 2020 For USD 150 Million 57

CSL Completes Private Placement Of Debt Securities Due 2025 For USD 100 Million 58

Asset Transactions 59

Paragon Care to Acquire Immunohaematology Business Unit from Seqirus for USD6.4 Million 59

Acquisition 60

CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 60

CSL Behring Acquires Calimmune 61

CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 62

CSL Ltd-Key Competitors 63

CSL Ltd-Key Employees 64

CSL Ltd-Locations And Subsidiaries 65

Head Office 65

Other Locations & Subsidiaries 65

Recent Developments 68

Strategy And Business Planning 68

Dec 07, 2017: Expansion of CSL Biotech Facility Drives Advanced Manufacturing Growth and Creates Victorian Jobs 68

Financial Announcements 69

Aug 15, 2018: CSL Delivers a Full Year Net Profit of USD 1.7 billion 69

Aug 16, 2017: CSL announces Full Year Result 2017 71

Feb 15, 2017: CSL Announces Half Year Result 2017 73

Jan 19, 2017: CSL reports FY2017 profit upgrade 75

Corporate Communications 76

Dec 13, 2017: CSL Appoints New Directors 76

Government and Public Interest 78

Oct 17, 2017: Australian Scientists awarded USD 2.5m to support ground-breaking medical research into cancer diagnostics and cardiovascular disease 78

Product News 79

09/14/2017: CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults 79

08/30/2017: Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference 80

08/09/2017: Berinert Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients 81

07/11/2017: CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders 82

06/15/2018: CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology 83

04/20/2018: CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting 84

03/16/2018: FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy 85

01/26/2018: CHMP Recommends Extension of Indications for Hizentra 86

Product Approvals 87

Jul 19, 2017: FDA Accepts CSL Behrings Supplemental Biologics License Application for Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication 87

Feb 14, 2017: FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition 88

Clinical Trials 89

Oct 03, 2018: Seqirus presents favorable outcomes data for adjuvanted trivalent influenza vaccine (FLUAD) at 6th Annual IDWeek 89

Nov 09, 2017: Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy 91

Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients 92

Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks 93

Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed 94

Appendix 95

Methodology 95

About GlobalData 95

Contact Us 95

Disclaimer 95


List Of Figure

List of Figures

CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

CSL Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

CSL Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

CSL Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13

CSL Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 19

Calimmune Raises USD15 Million in Series B Financing 23

CSL Enters into Agreement with Vitaeris 24

PaxVax Enters into Distribution Agreement with Seqirus 25

Seqirus Enters into Distribution Agreement with Valneva 26

A1M Pharma Enters into Research Agreement with CSL Behring 27

PaxVax Enters into Distribution Agreement with BioCSL 28

Alk Abello Enters into Co-Marketing Agreement with BioCSL 29

ALK-Abello Enters into Agreement with Seqirus 30

Seqirus Enters into Licensing Agreement with Glenmark Specialty 31

CSL Enters into Licensing Agreement with Cevec Pharma 32

CSL Enters into Licensing Agreement with Momenta Pharma 33

Seqirus Enters into Licensing Agreement with Zambon 35

Calimmune Enters into Licensing Agreement with Cincinnati Children's Hospital Medical Center 36

Calimmune Enters into Licensing Agreement with Asklepios BioPharma 37

Calimmune Enters into Licensing Agreement with St. Jude Children's Research Hospital 38

BioCryst Pharma Enters into Licensing Agreement with Seqirus 39

Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 41

CSL Enters Into Licensing Agreement With Janssen For CSL-362 42

CSL Enters into Licensing Agreement with Xencor 43

Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 44

CSL Raises USD200 Million in Private Placement of 3.32% Debt Securities Due 2029 45

CSL Raises USD150 Million in Private Placement of 3.47% Debt Securities Due 2032 46

CSL Raises USD100 Million in Private Placement of 3.77% Debt Securities Due 2037 47

CSL Raises USD250 Million in Private Placement of 3.17% Debt Securities Due 2027 48

CSL Raises USD258 Million in Private Placement of 0.955% Debt Securities Due 2025 49

CSL Raises USD155 Million in Private Placement of 0.755% Debt Securities Due 2023 50

CSL Raises USD100 Million in Private Placement of 3.63% Debt Securities Due 2025 51

CSL Raises USD200.5 Million in Private Placement of 1.93% Debt Securities Due 2024 52

CSL Raises USD134 Million in Private Placement of 2.1% Debt Securities Due 2026 53

CSL Raises USD134 Million in Private Placement of 1.65% Debt Securities Due 2022 54

CSL Completes Private Placement Of Debt Securities Due 2023 For USD 150 Million 55

CSL Completes Private Placement Of Debt Securities Due 2018 For USD 100 Million 56

CSL Completes Private Placement Of Debt Securities Due 2020 For USD 150 Million 57

CSL Completes Private Placement Of Debt Securities Due 2025 For USD 100 Million 58

Paragon Care to Acquire Immunohaematology Business Unit from Seqirus for USD6.4 Million 59

CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 60

CSL Behring Acquires Calimmune 61

CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 62

CSL Ltd, Key Competitors 63

CSL Ltd, Key Employees 64

CSL Ltd, Other Locations 65

CSL Ltd, Subsidiaries 65

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

CSL Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of bleeding disorders such as hemophilia and von Willebrand disease, hereditary angioedema, primary and secondary immune deficiencies, inherited respiratory disease and neurological disorders; influenza vaccine; and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns and infection in solid organ transplant recipients and to treat specific infections and help victims of trauma, shock and burns. CSL also markets an array of vaccines, anti-venoms, and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the UK, the US and rest of the world. CSL is headquartered in Parkville, Victoria, Australia.

CSL Ltd (CSL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

CSL Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13

CSL Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

CSL Ltd, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 19

Venture Financing 23

Calimmune Raises USD15 Million in Series B Financing 23

Partnerships 24

CSL Enters into Agreement with Vitaeris 24

PaxVax Enters into Distribution Agreement with Seqirus 25

Seqirus Enters into Distribution Agreement with Valneva 26

A1M Pharma Enters into Research Agreement with CSL Behring 27

PaxVax Enters into Distribution Agreement with BioCSL 28

Alk Abello Enters into Co-Marketing Agreement with BioCSL 29

ALK-Abello Enters into Agreement with Seqirus 30

Licensing Agreements 31

Seqirus Enters into Licensing Agreement with Glenmark Specialty 31

CSL Enters into Licensing Agreement with Cevec Pharma 32

CSL Enters into Licensing Agreement with Momenta Pharma 33

Seqirus Enters into Licensing Agreement with Zambon 35

Calimmune Enters into Licensing Agreement with Cincinnati Children's Hospital Medical Center 36

Calimmune Enters into Licensing Agreement with Asklepios BioPharma 37

Calimmune Enters into Licensing Agreement with St. Jude Children's Research Hospital 38

BioCryst Pharma Enters into Licensing Agreement with Seqirus 39

Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 41

CSL Enters Into Licensing Agreement With Janssen For CSL-362 42

CSL Enters into Licensing Agreement with Xencor 43

Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 44

Debt Offering 45

CSL Raises USD200 Million in Private Placement of 3.32% Debt Securities Due 2029 45

CSL Raises USD150 Million in Private Placement of 3.47% Debt Securities Due 2032 46

CSL Raises USD100 Million in Private Placement of 3.77% Debt Securities Due 2037 47

CSL Raises USD250 Million in Private Placement of 3.17% Debt Securities Due 2027 48

CSL Raises USD258 Million in Private Placement of 0.955% Debt Securities Due 2025 49

CSL Raises USD155 Million in Private Placement of 0.755% Debt Securities Due 2023 50

CSL Raises USD100 Million in Private Placement of 3.63% Debt Securities Due 2025 51

CSL Raises USD200.5 Million in Private Placement of 1.93% Debt Securities Due 2024 52

CSL Raises USD134 Million in Private Placement of 2.1% Debt Securities Due 2026 53

CSL Raises USD134 Million in Private Placement of 1.65% Debt Securities Due 2022 54

CSL Completes Private Placement Of Debt Securities Due 2023 For USD 150 Million 55

CSL Completes Private Placement Of Debt Securities Due 2018 For USD 100 Million 56

CSL Completes Private Placement Of Debt Securities Due 2020 For USD 150 Million 57

CSL Completes Private Placement Of Debt Securities Due 2025 For USD 100 Million 58

Asset Transactions 59

Paragon Care to Acquire Immunohaematology Business Unit from Seqirus for USD6.4 Million 59

Acquisition 60

CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 60

CSL Behring Acquires Calimmune 61

CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 62

CSL Ltd-Key Competitors 63

CSL Ltd-Key Employees 64

CSL Ltd-Locations And Subsidiaries 65

Head Office 65

Other Locations & Subsidiaries 65

Recent Developments 68

Strategy And Business Planning 68

Dec 07, 2017: Expansion of CSL Biotech Facility Drives Advanced Manufacturing Growth and Creates Victorian Jobs 68

Financial Announcements 69

Aug 15, 2018: CSL Delivers a Full Year Net Profit of USD 1.7 billion 69

Aug 16, 2017: CSL announces Full Year Result 2017 71

Feb 15, 2017: CSL Announces Half Year Result 2017 73

Jan 19, 2017: CSL reports FY2017 profit upgrade 75

Corporate Communications 76

Dec 13, 2017: CSL Appoints New Directors 76

Government and Public Interest 78

Oct 17, 2017: Australian Scientists awarded USD 2.5m to support ground-breaking medical research into cancer diagnostics and cardiovascular disease 78

Product News 79

09/14/2017: CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults 79

08/30/2017: Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference 80

08/09/2017: Berinert Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients 81

07/11/2017: CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders 82

06/15/2018: CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology 83

04/20/2018: CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting 84

03/16/2018: FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy 85

01/26/2018: CHMP Recommends Extension of Indications for Hizentra 86

Product Approvals 87

Jul 19, 2017: FDA Accepts CSL Behrings Supplemental Biologics License Application for Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication 87

Feb 14, 2017: FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition 88

Clinical Trials 89

Oct 03, 2018: Seqirus presents favorable outcomes data for adjuvanted trivalent influenza vaccine (FLUAD) at 6th Annual IDWeek 89

Nov 09, 2017: Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy 91

Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients 92

Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks 93

Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed 94

Appendix 95

Methodology 95

About GlobalData 95

Contact Us 95

Disclaimer 95


List Of Figure

List of Figures

CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

CSL Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

CSL Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

CSL Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13

CSL Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 19

Calimmune Raises USD15 Million in Series B Financing 23

CSL Enters into Agreement with Vitaeris 24

PaxVax Enters into Distribution Agreement with Seqirus 25

Seqirus Enters into Distribution Agreement with Valneva 26

A1M Pharma Enters into Research Agreement with CSL Behring 27

PaxVax Enters into Distribution Agreement with BioCSL 28

Alk Abello Enters into Co-Marketing Agreement with BioCSL 29

ALK-Abello Enters into Agreement with Seqirus 30

Seqirus Enters into Licensing Agreement with Glenmark Specialty 31

CSL Enters into Licensing Agreement with Cevec Pharma 32

CSL Enters into Licensing Agreement with Momenta Pharma 33

Seqirus Enters into Licensing Agreement with Zambon 35

Calimmune Enters into Licensing Agreement with Cincinnati Children's Hospital Medical Center 36

Calimmune Enters into Licensing Agreement with Asklepios BioPharma 37

Calimmune Enters into Licensing Agreement with St. Jude Children's Research Hospital 38

BioCryst Pharma Enters into Licensing Agreement with Seqirus 39

Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 41

CSL Enters Into Licensing Agreement With Janssen For CSL-362 42

CSL Enters into Licensing Agreement with Xencor 43

Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 44

CSL Raises USD200 Million in Private Placement of 3.32% Debt Securities Due 2029 45

CSL Raises USD150 Million in Private Placement of 3.47% Debt Securities Due 2032 46

CSL Raises USD100 Million in Private Placement of 3.77% Debt Securities Due 2037 47

CSL Raises USD250 Million in Private Placement of 3.17% Debt Securities Due 2027 48

CSL Raises USD258 Million in Private Placement of 0.955% Debt Securities Due 2025 49

CSL Raises USD155 Million in Private Placement of 0.755% Debt Securities Due 2023 50

CSL Raises USD100 Million in Private Placement of 3.63% Debt Securities Due 2025 51

CSL Raises USD200.5 Million in Private Placement of 1.93% Debt Securities Due 2024 52

CSL Raises USD134 Million in Private Placement of 2.1% Debt Securities Due 2026 53

CSL Raises USD134 Million in Private Placement of 1.65% Debt Securities Due 2022 54

CSL Completes Private Placement Of Debt Securities Due 2023 For USD 150 Million 55

CSL Completes Private Placement Of Debt Securities Due 2018 For USD 100 Million 56

CSL Completes Private Placement Of Debt Securities Due 2020 For USD 150 Million 57

CSL Completes Private Placement Of Debt Securities Due 2025 For USD 100 Million 58

Paragon Care to Acquire Immunohaematology Business Unit from Seqirus for USD6.4 Million 59

CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 60

CSL Behring Acquires Calimmune 61

CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 62

CSL Ltd, Key Competitors 63

CSL Ltd, Key Employees 64

CSL Ltd, Other Locations 65

CSL Ltd, Subsidiaries 65

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

CSL Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.